82/100 · Critical
Manufactured by Vitruvias Therapeutics, Inc.
Pramipexole Dihydrochloride Adverse Events Show High Seriousness and Diverse Reactions
12,761 FDA adverse event reports analyzed
Last updated: 2026-05-12
PRAMIPEXOLE DIHYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Vitruvias Therapeutics, Inc.. Based on analysis of 12,761 FDA adverse event reports, PRAMIPEXOLE DIHYDROCHLORIDE has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for PRAMIPEXOLE DIHYDROCHLORIDE include DRUG INEFFECTIVE, FATIGUE, OFF LABEL USE, PAIN, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PRAMIPEXOLE DIHYDROCHLORIDE.
Pramipexole Dihydrochloride has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 12,761 adverse event reports for this medication, which is primarily manufactured by Vitruvias Therapeutics, Inc..
The most commonly reported adverse events include Drug Ineffective, Fatigue, Off Label Use. Of classified reports, 74.4% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. High percentage of serious adverse events (74.4%) indicates significant safety concerns.
A wide range of reactions, including neurological, gastrointestinal, and respiratory issues, suggests diverse safety risks. Falls and pneumonia are notable among frequent adverse events, indicating potential risks in elderly patients.
Patients taking Pramipexole Dihydrochloride should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Pramipexole dihydrochloride can cause drug interactions, and patients should be monitored for adverse reactions, especially when combined with other medications. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Pramipexole Dihydrochloride received a safety concern score of 82/100 (high concern). This is based on a 74.4% serious event ratio across 4,421 classified reports. The score accounts for 12,761 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 2,355, Male: 1,535, Unknown: 1. The most frequently reported age groups are age 78 (148 reports), age 67 (104 reports), age 75 (102 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 4,421 classified reports for PRAMIPEXOLE DIHYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Pramipexole dihydrochloride can cause drug interactions, and patients should be monitored for adverse reactions, especially when combined with other medications.
If you are taking Pramipexole Dihydrochloride, here are important things to know. The most commonly reported side effects include drug ineffective, fatigue, off label use, pain, headache. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should inform their healthcare provider about any pre-existing conditions or current medications to avoid potential drug interactions. Regular monitoring and follow-up appointments are recommended to assess the safety and efficacy of pramipexole dihydrochloride. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor pramipexole dihydrochloride for safety, and healthcare providers should report any adverse events to the FDA's MedWatch program.
The FDA has received approximately 12,761 adverse event reports associated with Pramipexole Dihydrochloride. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Pramipexole Dihydrochloride include Drug Ineffective, Fatigue, Off Label Use, Pain, Headache. By volume, the top reported reactions are: Drug Ineffective (476 reports), Fatigue (334 reports), Off Label Use (287 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Pramipexole Dihydrochloride.
Out of 4,421 classified reports, 3,290 (74.4%) were classified as serious and 1,131 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Pramipexole Dihydrochloride break down by patient sex as follows: Female: 2,355, Male: 1,535, Unknown: 1. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Pramipexole Dihydrochloride adverse events are: age 78: 148 reports, age 67: 104 reports, age 75: 102 reports, age 65: 100 reports, age 72: 97 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Pramipexole Dihydrochloride adverse event reports is Vitruvias Therapeutics, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Pramipexole Dihydrochloride include: Nausea, Fall, Insomnia, Pneumonia, Condition Aggravated. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Pramipexole Dihydrochloride to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Pramipexole Dihydrochloride has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. High percentage of serious adverse events (74.4%) indicates significant safety concerns.
Key safety signals identified in Pramipexole Dihydrochloride's adverse event data include: High incidence of serious adverse events like pneumonia and falls.. Neurological issues such as hallucinations and dyskinesia are frequently reported.. Gastrointestinal issues like nausea and vomiting are common.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Pramipexole dihydrochloride can cause drug interactions, and patients should be monitored for adverse reactions, especially when combined with other medications. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Pramipexole Dihydrochloride.
Patients should inform their healthcare provider about any pre-existing conditions or current medications to avoid potential drug interactions. Regular monitoring and follow-up appointments are recommended to assess the safety and efficacy of pramipexole dihydrochloride.
Pramipexole Dihydrochloride has 12,761 adverse event reports on file with the FDA. A wide range of reactions, including neurological, gastrointestinal, and respiratory issues, suggests diverse safety risks. The volume of reports for Pramipexole Dihydrochloride reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor pramipexole dihydrochloride for safety, and healthcare providers should report any adverse events to the FDA's MedWatch program. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with PRAMIPEXOLE DIHYDROCHLORIDE:
Drugs related to PRAMIPEXOLE DIHYDROCHLORIDE based on therapeutic use, drug class, or shared indications: